LncRNA FENDRR suppresses the progression of NSCLC via regulating miR-761/TIMP2 axis - 18/09/19

pages | 11 |
Iconographies | 8 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | FENDRR is downregulated in NSCLC and inversely associated with prognosis. |
• | FENDRR inhibits the aggressiveness of NSCLC depend on miR-761. |
• | TIMP2 is identified as the downstream target of miR-761. |
• | FENDRR suppresses the progression of NSCLC via regulating miR-761/TIMP2. |
Abstract |
To explore the roles of long noncoding RNA (lncRNA) FOXF1 Adjacent Non-Coding Developmental Regulatory RNA (FENDRR) in human non-small cell lung cancer (NSCLC). The levels of FENDRR in NSCLC cells and tissues were analyzed using qRT-PCR assay. The growth and colony formation abilities of NSCLC cell were analyzed by the MTT and colony formation tests. The mobility and invasiveness of NSCLC cell were analyzed using the wound closure and Transwell invasion assay. The impact of FENDRR on the tumor growth of NSCLC cells in vivo was detected using xenograft model. Bioinformatics analysis and luciferase reporter gene bioassay were selected to identify the bindings sites between miR-761 and FENDRR. Additional, the results of Transwell invasion and colony formation experiments indicated that FENDRR inhibited the aggressiveness of NSCLC depend on miR-761. Tissue inhibitor of metalloproteinase 2 (TIMP2) was identified as the downstream target of miR-761 and its level was positively regulated by FENDRR. Cotransfection assays using A549 and H1975 cells future implied that downexpression of TIMP2 rescued the aggressiveness phenotypes of NSCLC cell inhibited by FENDRR. Altogether, we demonstrated that lncRNA FENDRR suppressed the progression of NSCLC via binding to miR-761 and regulating TIMP2 expression.
Le texte complet de cet article est disponible en PDF.Keywords : NSCLC, FENDRR, MiR-761, TIMP2, Migration, Invasion
Plan
Vol 118
Article 109309- octobre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?